If you had started a Rs 10,000 monthly SIP in a Nippon India fund twenty years ago and stayed invested without a break, your money would be worth close to Rs 2 crore today. Not a projection. Not a sales pitch. That is what the actual return data shows.
Three funds from the Nippon India stable have managed something few funds can claim. They have delivered more than 15 percent SIP returns across every long stretch that matters, 5 years, 10 years, 15 years and 20 years, according to Value Research. In a market where most funds struggle to hold a strong run even over five years, that kind of consistency is worth a closer look.
The three funds are Nippon India Pharma Fund – Direct Plan – Growth, Nippon India Growth Mid Cap Fund – Direct Plan – Growth and Nippon India Multi Cap Fund – Direct Plan – Growth. All three are regular plans. Here is how their SIP returns stack up.
| Fund | 3-year SIP XIRR | 5-year | 10-year | 15-year | 20-year |
| Nippon India Pharma Fund | 13.68% | 17.08% | 17.99% | 16.76% | 18.06% |
| Nippon India Growth Mid Cap Fund | 13.49% | 19.03% | 20.15% | 18.72% | 16.91% |
| Nippon India Multi Cap Fund | 7.99% | 15.05% | 17.16% | 15.98% | 15.80% |
Notice something. None of the three crossed 15 percent over the last three years. Pharma Fund’s three-year number is 13.68 percent, Growth Mid Cap is at 13.49 percent, and Multi Cap trails at just 7.99 percent, according to Value Research. It is only when you stretch the horizon to 5 years and beyond that the real strength of these funds shows up. That gap is the first lesson of this story, long-term SIPs smooth out short-term bumps.
Now translate those long-term numbers into rupees. Here is what a Rs 10,000 monthly SIP would be worth today if you had started it 20 years ago and stayed invested through market crashes, rallies and everything in between.
| Fund | Value of Rs 10,000 monthly SIP over 20 years |
| Nippon India Pharma Fund | Rs 1.96 crore |
| Nippon India Growth Mid Cap Fund | Rs 1.69 crore |
| Nippon India Multi Cap Fund | Rs 1.47 crore |
Nippon India Pharma Fund leads the pack, turning a total investment of Rs 24 lakh into close to Rs 2 crore. Growth Mid Cap and Multi Cap are not far behind, each comfortably crossing Rs 1.4 crore.
Why regular plans and not direct plans? Because direct plans are a relatively recent invention. SEBI introduced them only on January 1, 2013, so most funds simply do not have 15-year or 20-year direct plan data to compare. Regular plans are the only fair way to look this far back.
Strong on lump sum too
These three funds are not one-trick ponies built only for SIP investors. They rank among the best performers on a lump-sum basis as well. Nippon India Pharma Fund sits in the top five funds over 10, 15 and 20 years, coming in 4th over 10 years and 3rd over both 15 and 20 years. Nippon India Growth Mid Cap Fund has returned 17.86 percent over 10 years, 17.76 percent over 15 years and 16.44 percent over 20 years on a lump-sum basis. Nippon India Multi Cap Fund has delivered 15.03 percent over 10 years, 15.96 percent over 15 years and 15.30 percent over 20 years, Value Research data shows. The consistency shows up whichever way you invest, monthly or in one shot.
The funds, up close
Nippon India Pharma Fund was launched in June 2004 and has delivered 19.97 percent since inception. It is a sectoral fund that bets almost entirely on pharma and healthcare companies, both domestic and export-facing, across large, established names and smaller high-growth ones. It managed assets of Rs 9,279 crore as of July 31, 2026, with an expense ratio of 1.51 percent, and is benchmarked against the BSE Healthcare TRI. Its riskometer reads Very High. The fund’s mean return over the data period is 18.16 percent with a standard deviation of 14.76 percent, a Sharpe ratio of 0.84 and a Sortino ratio of 1.22.
| Top holdings, Nippon India Pharma Fund | Weight |
| Sun Pharmaceutical | 13.31% |
| Lupin | 7.25% |
| Divi’s Laboratories | 6.52% |
| Cipla | 6.03% |
| Apollo Hospitals | 5.30% |
| Dr. Reddy’s Laboratories | 5.01% |
| Mankind Pharma | 3.74% |
| Sai Life Sciences | 3.62% |
| Ajanta Pharma | 3.41% |
| Max Healthcare | 3.15% |
Its top 10 holdings alone account for about 57 percent of the portfolio, so this is a concentrated bet on one sector. Sun Pharmaceutical is the single largest holding at over 13 percent.
Nippon India Growth Mid Cap Fund has been around much longer, launched way back in October 1995. It tracks the NIFTY Midcap 150 TRI and has returned 21.93 percent since inception. With assets of Rs 50,751 crore as of July 31, 2026, it is one of the largest funds in the mid-cap category, and carries an expense ratio of 1.24 percent. Its mean return works out to 20.29 percent with a standard deviation of 17.81 percent, a Sharpe ratio of 0.82 and a Sortino ratio of 1.08, all ahead of its benchmark on a risk-adjusted basis.
| Top holdings, Nippon India Growth Mid Cap Fund | Weight |
| The Federal Bank | 2.90% |
| AU Small Finance Bank | 2.74% |
| BSE | 2.73% |
| Info Edge (India) | 2.61% |
| Fortis Healthcare | 2.55% |
| REC | 2.50% |
| Eternal | 2.38% |
| Bharat Forge | 2.36% |
| MCX | 2.28% |
| ICICI Bank | 1.98% |
Unlike the Pharma fund, this one spreads its bets wide. The top 10 holdings add up to just about 25 percent of assets, spanning financials, technology, healthcare and consumer names.
Nippon India Multi Cap Fund, launched in March 2005, goes across large, mid and small caps, benchmarked against the Nifty 500 Multicap 50:25:25 TRI. It has returned 17.32 percent since inception and managed assets of Rs 55,587 crore as of July 31, 2026, with an expense ratio of 1.21 percent. Its mean return is 14.65 percent with a standard deviation of 15.31 percent, a Sharpe ratio of 0.58 and a Sortino ratio of 0.78, both ahead of its benchmark.
| Top holdings, Nippon India Multi Cap Fund | Weight |
| HDFC Bank | 7.10% |
| Axis Bank | 4.92% |
| ICICI Bank | 4.41% |
| Infosys | 3.87% |
| Bajaj Finance | 1.97% |
| NTPC | 1.86% |
| Linde India | 1.85% |
| Swiggy | 1.80% |
| Reliance Industries | 1.78% |
| Larsen & Toubro | 1.77% |
Its heaviest tilt is towards financials, led by HDFC Bank at 7.10 percent, with the rest of the portfolio touching technology, energy, utilities, materials and industrials.
All three funds carry a Very High risk rating. That is the price of the returns above. Pharma Fund’s fortunes rise and fall with one sector. The two diversified funds carry the usual mid-cap and multi-cap volatility that comes with owning smaller, faster-growing businesses.
A word of caution
Numbers like Rs 2 crore from a Rs 10,000 SIP are hard to ignore, and that is exactly the problem. Past returns, however strong, are not a promise of what comes next. A fund that has beaten the market for 20 years can still go through a rough three-year patch, as the data above already shows. Before picking a fund only for its return history, look at what it actually invests in, how concentrated or spread out its portfolio is, how much risk it carries, and whether that risk fits your own goals and time horizon. Returns tell you what happened. They do not tell you what will happen, and they should never be the only reason to invest.
Disclaimer: Past performance does not guarantee future returns. The SIP values and returns mentioned are based on historical data and are for illustration only. Mutual fund investments are subject to market risks. Investors should consider their investment goals, risk appetite and time horizon before investing.
Every financial journey has a turning point. What’s yours?
Financial Express is launching a new series highlighting real experiences with money, investments, and the taxman. Did a sudden tax rule catch you off guard? Did a piece of financial advice change your life? Your story could provide invaluable, practical lessons for thousands of fellow taxpayers. Share your experience with us. We respect your privacy: no stories will be featured without a direct conversation and your full consent. Thank you.